Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Other Operating Expenses (2016 - 2025)

BioCorRx's Other Operating Expenses history spans 16 years, with the latest figure at -$586370.0 for Q3 2025.

  • For Q3 2025, Other Operating Expenses rose 60.58% year-over-year to -$586370.0; the TTM value through Sep 2025 reached -$2.6 million, up 34.61%, while the annual FY2024 figure was $2846.0, 96.66% down from the prior year.
  • Other Operating Expenses for Q3 2025 was -$586370.0 at BioCorRx, up from -$1.2 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $154586.0 in Q3 2021 and bottomed at -$1.5 million in Q3 2024.
  • The 5-year median for Other Operating Expenses is $2727.0 (2021), against an average of -$337502.8.
  • The largest annual shift saw Other Operating Expenses soared 3012.08% in 2023 before it plummeted 35717.5% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $2727.0 in 2021, then surged by 228.97% to $8971.0 in 2022, then skyrocketed by 48.79% to $13348.0 in 2023, then tumbled by 97.78% to $296.0 in 2024, then crashed by 198197.97% to -$586370.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Other Operating Expenses are -$586370.0 (Q3 2025), -$1.2 million (Q2 2025), and -$875817.0 (Q1 2025).